Oragenics Inc
oragenics.comWhat Do They Do?
Develops nasal-delivery drug candidates for neurological conditions, including a treatment candidate for concussion and mild traumatic brain injury.
10-K for FY2025, filed Mar 16, 2026We are a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies…View ↗
Our lead product and focus are on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (“mTBI”…View ↗
ONP-002, together with our other neurology assets, are referred to herein as the Neurology Assets. To date, ONP-002 has been shown to be…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
−$2.5MView ↗
- ▲ +11% (Loss)
- vs −$2.3M in Q2 FY2025
-
Aug 28, 2026
NYSE American found Oragenics out of compliance with listing standards
The company must submit a plan to regain compliance; its shares remain listed during the plan period if the exchange accepts it.
Sources
8-K, filed Aug 28, 2026
On August 26, 2026, Oragenics, Inc. (the “Company”) received notification (the “Notice”) from the NYSE American LLC (the “NYSE American”)…View ↗
-
May 7, 2026
Signed a letter of intent to license CardioDialysis for brain injury treatment
The proposed exclusive license would cover traumatic brain injury and other chronic neurodegenerative diseases, subject to a definitive agreement and closing conditions.
Sources
8-K, filed May 7, 2026
On May 7, 2026, Oragenics, Inc. (the “Company”) issued a press release announcing that it has signed a Letter of Intent (“LOI”) with Sigyn…View ↗
From infectious disease to neurology
The older report centered on a coronavirus vaccine and antibiotic candidates; the latest centers on a nasal drug candidate for concussion and mild traumatic brain injury.
10-K for FY2022, filed Apr 17, 2023 10-K for FY2025, filed Mar 16, 2026
Who Do They Compete With?
Competes with Merck &, GlaxoSmithKline, CSL, Sanofi Pasteur, Pfizer, Johnson & Johnson, AstraZeneca, and Moderna
10-K for FY2025, filed Mar 16, 2026Many of our existing and potential competitors are large, well-established pharmaceutical, chemical or healthcare companies with…View ↗
Loading...
